Behrad Derakhshan, Ph.D.

Behrad Derakhshan, Ph.D.

Chief Operating OfficeratEdgewise Therapeutics· In proxies 2022–2025

Pay in FY2025+1% from the year before · Edgewise Therapeutics stock -7.1% the same year

Behrad Derakhshan, Ph.D. was paid $2.9M in FY2025 (Dec), up 1%. Edgewise Therapeutics stock fell 7.1% that year.

Pay$100 in the stock at the end of FY21 → $162
Pay is from the Summary Compensation Table of each Edgewise Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Edgewise TherapeuticsPublic company · 4 yr
    • Chief Operating Officer2022 – Present · 4 yrStock in role +181%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?